

Capital and Business Alliance with GlyTech, Inc.

Tokyo, November 1, 2022 – KH Neochem Co., Ltd. (TSE: 4189, President and CEO: Michio Takahashi, “KH Neochem”) announced its capital participation in GlyTech, Inc. (“GlyTech”) by subscribing to a third-party allotment of new shares in October 2022.

Glycans, called the third chain of life for their function in vivo similar to nucleic acids and proteins, are known for their involvement in various biological phenomena such as cellular differentiation, metabolism, immune response, cancer metastasis, viral infection, aging, and transmission of information via cranial nerves. While research and development is being actively conducted in the life science field such as the development of new drugs, the organic synthesis of glycans is difficult due to their structural diversity. The mass production and stable supply of glycans are issues for the further advancement and promotion of scientific and industrial use. GlyTech is a start-up with glycan mass production technologies and glycan modification technologies capable of conjugation of glycans to proteins and peptides that are active ingredients in biopharmaceuticals. Utilizing these platform technologies, GlyTech provides drug discovery support in the form of contract research on new drug candidate substances and the sale of glycans to pharmaceutical companies, chemical manufacturers, universities, and research institutions in Japan and overseas.

KH Neochem has designated “Environment, Healthcare, Electronics” as its strategic domains for the realization of VISION 2030, and has aimed to create new businesses. In the healthcare domain, KH Neochem has focused on the potential of glycans, and has developed proprietary glycans and manufacturing technologies. The strengthening of the relationship through this investment, as well as the joint research on glycan manufacturing currently underway with GlyTech, will serve to accelerate activities working towards the mass production and stable supply of various types of glycans. If glycans that show individual difference in vivo expression could be mass produced, this would promote the development of personalized medicine tailored to each individual such as biopharmaceuticals and diagnostic drugs for cancer and lifestyle diseases, which is anticipated to lead to a significant improvement in individual quality of life. KH Neochem aims to further contribute to enriching the lives of people around the world through the development of technologies such as the manufacturing of high-purity glycans.

This is KH Neochem’s second investment in a start-up, following its first investment in April of this year.

KH Neochem will continue to work on the creation of new business by actively utilizing open innovation that deepens collaborative creation with outside parties to resolve social issues.

[About GlyTech]

Address: Kyoto
Date of establishment: April 2, 2012
President & CEO: Mr. Hiroaki Asai
Business description: Supporting the development of innovative and improved medicines, such as biopharmaceuticals based on the glycan production and chemical glycosylation technologies.
URL: <https://www.glytech-inc.com>

■ Contact information for this matter

Public Relations

KH Neochem Co., Ltd.

kouhou@khneochem.co.jp

###